VPS33A and mucopolysaccharidosis: While reporting a case displaying mucopolysaccharidosis plus, a rare and attenuated subtype of mucopolysaccharidosis related to the VPS33A protein, Pavlova and co-workers described the effects of bortezomib and eliglustat in improving glycosphingolipid trafficking in patient-derived fibroblasts [71].